Table 2.  .

Characteristics of the laboratory blood test results

Parameter	Control group		Investigation group (Thymalin)		p 1	p 2	p 3	p 4
	before the treatment	on the 14th day of treatment	before the treatment	on the 14th day of treatment
WBC, cells × 109/L	6.59 ± 0.76	7.79 ± 1.15	6.01 ± 0.61	7.52 ± 0.59	0.048	0.001	0.40	0.72
Lymphocytes, cells × 109/L	0.89 ± 0.12	0.96 ± 0.17	0.61 ± 0.09	1.17 ± 0.20	0.12	<0.001	0.002	0.077
Monocytes, cells × 109/L	0.45 ± 0.06	0.64 ± 0.09	0.38 ± 0.05	0.59 ± 0.08	0.001	<0.001	0.20	0.43
Neutrophils, cells × 109/L	5.33 ± 0.35	5.73 ± 1.03	5.52 ± 0.28	5.31 ± 0.93	0.027	0.55	0.78	0.12
Platelets, cells × 109/L	192 ± 18.1	259 ± 23.0	205 ± 19.3	293 ± 22.0	<0.001	<0.001	0.46	0.04
Lymphocytes/monocytes	2.11 ± 0.24	1.74 ± 0.19	2.04 ± 0.22	2.21 ± 0.25	0.088	0.48	0.79	0.065
Platelets/WBC	31.2 ± 2.9	36.8 ± 3.9	39.5 ± 4.7	44.1 ± 6.1	0.15	0.45	0.043	0.20
Platelets/lymphocytes	253 ± 37	306 ± 42	270 ± 31	344 ± 34	0.004	0.002	0.07	0.26
Fibrinogen, g/L	7.5 ± 1.22	6.84 ± 1.09	8.87 ± 0.63	6.81 ± 0.53	0.078	<0.001	0.023	0.94
APTT, s	44.7 ± 4.6	44.3 ± 5.1	47.8 ± 4.61	50.2 ± 4.74	0.48	0.054	0.29	0.017
CRP, mg/L	25.2 ± 3.4	11.6 ± 1.33	47.4 ± 3.8	14.5 ± 0.87	0.003	<0.001	<0.001	0.018
IL-6, pg/mL	121 ± 22.5	88.7 ± 14.8	155 ± 20.5	24.2 ± 2.5	0.76	0.012	0.33	0.001
D-dimer, ng/mL	965 ± 112	994 ± 97	1030 ± 103	688 ± 57	0.78	0.003	0.63	0.003
LDH, U/L	787 ± 76	688 ± 70	832 ± 65	445 ± 39	0.64	<0.001	0.71	0.001
Eosinophils, cells × 109/L	26.1 ± 2.1	81.8 ± 7.7	22.2 ± 2.9	102 ± 9.2	<0.001	<0.001	0.50	0.28
T lymphocytes, cells/μL	498 ± 57	424 ± 62	287 ± 22	632 ± 27	0.53	0.006	0.005	0.003
CD4+, cells/μL	173 ± 31	193 ± 25	149 ± 18.5	333 ± 33.4	0.84	<0.001	0.3	0.001
CD8+, cells/μL	168 ± 33.5	216 ± 39.7	127 ± 23.3	277 ± 37	0.14	0.009	0.16	0.35
CD3+HLA-DR+, cells/μL	33 ± 4.7	42.5 ± 5.9	19.6 ± 1.4	66.8 ± 3.2	0.17	0.003	0.008	0.002
CD4/CD8	1.64 ± 0.14	0.78 ± 0.19	1.15 ± 0.21	1.25 ± 0.25	0.054	0.057	0.07	0.049
B-lymphocytes, cells/μL	98.8 ± 12.6	90.2 ± 9.4	63.2 ± 7.1	125 ± 17.3	0.70	0.017	0.019	0.15
NK cells, cells/μL	106 ± 9.8	96.5 ± 8.4	49.3 ± 3.7	119 ± 8.6	0.64	0.003	<0.001	0.43

WBS—white blood cells (leucocytes); APTT—activated partial thromboplastin time; CRP—C-reactive protein; LDH—lactatdegydrogenase; NK—natural killers. Wilcoxon signed rank test (pairwise) with Hommel correction for multiple comparisons: p₁—control group before the treatment vs. control group on the 14th day of the treatment; p₂—investigation group (Thymalin) before the treatment vs. investigation group (Thymalin) on the 14th day of the treatment. Wilcoxon rank sum test with Hommel correction for multiple comparisons: p₃—control group before the treatment vs. investigation group (Thymalin) before the treatment; p₄—control group on the 14th day of the treatment vs. investigation group (Thymalin) on the 14th day of the treatment. The values of the significance level p are highlighted in bold, indicating significant differences between the groups.